Compelo Medical Devices - Latest industry news and analysis is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More

IntelligentMDx obtains CE Mark approval for artus C. difficile QS-RGQ kit

US-based IntelligentMDx (IMDx) has obtained CE Mark approval for its artus C. difficile QS-RGQ kit for use with QIAsymphony SP/AS and Rotor-Gene Q instruments.

This is the first of a series of assays designed, developed, and manufactured by IMDx for Qiagen under a multi-year development and license agreement.

In December 2013, the company has filed a 510(k) premarket notification with the US Food and Drug Administration (FDA) for the test.

IMDx’s artus C. difficile QS-RGQ kit detects the presence of Clostridium difficile (C. difficile), the most common cause of hospital-associated diarrhea. The kit detects C. difficile in human liquid or soft stool from patients suspected of having C. difficile-associated disease.

The test is intended to be used directly on patient samples to help in diagnosis of C. difficile infection.

IMDx chairman and CEO Dr Alice Nesselrodt noted CE-marking of the artus C. difficile QS-RGQ kit is the first step toward the company’s mission of making new tests available globally to customers using QIAsymphony SP/AS and Rotor-Gene Q instruments.

"We are looking forward to continuing our partnership with QIAGEN in 2014 with the CE-marking and 510(k) submissions of other products currently in our development pipeline," Dr Nesselrodt added.